Skip to content
Medical Health Aged Care, Mental Health

Mental health nurses and clinicians key to reducing recreational cannabis harm

Charles Darwin University 2 mins read

Harm caused by recreational cannabis could be reduced if mental health nurses are better equipped with information on the risks and benefits of the substance, according to a joint study with Charles Darwin University (CDU).

The study with CDU and Chiang Mai University in Thailand examined literature on the medicinal benefits of cannabis, the negative mental health impacts associated with legalising recreational use and strategies to minimise these harms. 

Corresponding author and CDU Professor in Mental Health Dan Bressington said as more countries move to legalise recreational cannabis, it was crucial for nurses and mental health clinicians to have the knowledge and resources to support patients using or exploring the substance.

“We found that legalisation of recreational cannabis use is likely to result in some deleterious effects on mental health, particularly for vulnerable groups such as adolescents, people with an existing severe mental illness and those with a family history of mental illnesses,” Professor Bressington said.

“However, based on the current evidence we should not expect dramatic changes in the volume of cannabis-related presentations to emergency departments and major increases in healthcare costs in the general population.

“Our review highlighted several key messages that mental health clinicians should aim to convey when working as a mental health educator, including not using it frequently, avoiding cannabis sativa strains with high potency THC content and not experimenting with cannabis until after 21 years old.

“We also propose several risk-reduction strategies on a population level, including regulatory and financial measures, the provision of tailored education and information health promotion programs, screening approaches, specialist treatment services and research and evaluation.”

On medical benefits of cannabis, Professor Bressington said there was strong evidence of efficacy in epilepsy, multiple sclerosis, and inflammatory bowel disorders.

Professor Bressington said the authors pursued the study after the sudden relaxation of Thailand’s cannabis use laws in 2022, following the legalisation of cannabis for medical use in 2018.

“The change in legislation has triggered a great deal of debate about the risks and potential benefits of cannabis legalisation, both within Thailand and internationally,” Professor Bressington said.

“Concerns generally relate to fears that more availability will result in increased frequency of use and a negative impact on mental health.

“As nurses and mental health clinicians we wanted to find out what impact cannabis legalisation may have on mental health in Thailand based on the evidence from other countries that have legalised recreational use.

“We need to help people make informed choices about their health behaviours and therefore collated relevant evidence that healthcare professionals may find useful if they are working with people that consume cannabis recreationally.”

The study was published in the Journal of Psychiatric and Mental Health Nursing.


Contact details:

Raphaella Saroukos she/her
Communications Officer
Marketing, Media & Communications
Larrakia Country
T: +61 8 8946 6721
E: [email protected]
W: cdu.edu.au


Media

More from this category

  • Medical Health Aged Care, Women
  • 19/12/2025
  • 16:00
Breast Cancer Network Australia

Affordable access to life extending drug for people with incurable breast cancer.

Key Facts: Tucatinib, a breast cancer drug, will be listed on PBS, saving patients over $4,500 per month The drug is specifically for HER2-positive metastatic breast cancer patients, particularly those with brain metastases Interviews: Larissa King - woman living with breast cancer that has spread to the brain Vicki Durston. BCNA Director Policy, Advocacy and Support Services. People with breast cancer that has spread to the brain will save more than $4500 a month when Tucatinib is listed on the Pharmaceutical Benefits Scheme in the coming weeks. Breast Cancer Network Australia (BCNA) welcomes today’s decision by the Pharmaceutical Benefits Advisory…

  • Medical Health Aged Care
  • 19/12/2025
  • 09:05
Royal Australian College of GPs

RACGP celebrates WA excellence in general practice at awards

The Royal Australian College of General Practitioners (RACGP) WA Faculty has honoured outstanding contributions to general practice at its annual awards ceremony, celebrating leaders, educators, registrars, and practices across the state. The evening provided the opportunity to celebrate the College’s highest honour, the Rose-Hunt Award, awarded during GP25, which was presented to WA GP, Adjunct Associate Professor Frank R Jones, recognising his 45 years of service to general practice, including 40 years at Murray Medical Centre in Mandurah. Professor Jones has worked across rural, procedural, and community settings and held numerous leadership roles within the RACGP, including President, Vice President,…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 22:11
BeOne Medicines Ltd.

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer FDA Fast Track Designation reflects the…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.